Loading
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
Latest quote
¥425
+¥10.00 · +2.41%
Regular session · JST · Market data may be delayed.
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
Regular session · JST · Market data may be delayed.
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 72.22M JPY | 80.04M JPY | 69.25M JPY | 391.83M JPY | 289.76M JPY |
| Cost of goods sold | — | — | — | 88.41M JPY | 71.6M JPY |
| Gross profit | 72.22M JPY | — | — | 303.42M JPY | 218.16M JPY |
| Research and development | 681.36M JPY | 643.27M JPY | 716.79M JPY | 533.29M JPY | 398.52M JPY |
| Selling, general, and administrative | 300.31M JPY | 254.65M JPY | 241.22M JPY | 196.29M JPY | 177.52M JPY |
| Operating expenses | 981.67M JPY | 897.92M JPY | 958.01M JPY | 729.58M JPY | 576.04M JPY |
| Interest income | 179K JPY | 189K JPY | 5K JPY | — | 1K JPY |
| Operating income | −909.45M JPY | −817.88M JPY | −888.76M JPY | −426.17M JPY | −357.88M JPY |
| Net income | −916.26M JPY | −756.45M JPY | −854.15M JPY | −331.83M JPY | −301.17M JPY |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
